Phase 1/2 study of Multiple-Vaccine with CpG-ODN Therapy in Patient with Refractory Colon Cancer to Chemotherapy.

Phase 1/2 study of Multiple-Vaccine with CpG-ODN Therapy in Patient with Refractory Colon Cancer to Chemotherapy. - Phase 1/2 study of Multiple-Vaccine with CpG-ODN Therapy in Patient with Refractory Colon Cancer to Chemotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002392

Enrollment

Registered

2009-08-28

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Interventions

RNF43,TOMM34,VEGFR1,VEGFR2 peptides restricted to HLA-A*2402 (3.0mg for each) are administered four times once a week. RNF43,TOMM34,VEGFR1,VEGFR2 peptides restricted to HLA-A*2402 (3.0mg for each) wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically and/or cytologically proven Colon Cancer, which is refractory to standard chemotherapy. 2.ECOG performance status 0-1 3.No severe postoperative complications 4.Age between 20 to 85 5.normal funcitons in vital organs 6.Life expectancy > 3 months 7.HLA-A*2402 8.Able and willing to give valid written informed consent

Exclusion criteria

Exclusion criteria: 1.Pregnancy 2.Breastfeeding 3.Concurrent treatment with steroids or immunosuppressing agent 4.No other malignancy requiring treatment 5.No severe cardio-vascular disease 6.Decision of unsuitableness by principal investigator or physician-in-charge

Design outcomes

Primary

Measure	Time frame
Evaluation of safety and specific immune response	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026